ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome

Introduction Adenosine deaminase( ADA) deficiency is an autosomal recessive primary immunodeficiency. It results in the intracellular accumulation of toxic metabolites which have effects particularly on lymphocytes and the brain. The aim of this study was to evaluate the outcome of 13 ADA-deficient patients. We planned to evaluate their clinical and laboratory findings before and after enzyme replacement therapy(ERT), allogeneic hematopoietic stem celltransplantation (aHSCT), and hematopoietic stem cellgene therapy (HSCGT).